Download PDF
CC BY 4.0 · Arq Neuropsiquiatr 2022; 80(12): 1254-1261
DOI: 10.1055/s-0042-1758864
Original Article

Clinicopathological and prognostic significance of COX-2 in glioma patients: a meta-analysis

Significância clinicopatológica e prognóstica da COX-2 em pacientes com glioma: uma metanálise
Jun Wang 
1   China Three Gorges University, The People's Hospital, Yichang, Hubei Province, China.
,
Chenyan Xiang 
1   China Three Gorges University, The People's Hospital, Yichang, Hubei Province, China.
,
Yi Cai 
2   China Three Gorges University, College of Basic Medical Sciences, Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, Yichang, Hubei, China.
3   China Three Gorges University, College of Basic Medical Sciences, The Institute of Infection and Inflammation, Yichang, China.
,
Ziyi Mei 
2   China Three Gorges University, College of Basic Medical Sciences, Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, Yichang, Hubei, China.
3   China Three Gorges University, College of Basic Medical Sciences, The Institute of Infection and Inflammation, Yichang, China.
,
Qianqian Lu 
2   China Three Gorges University, College of Basic Medical Sciences, Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, Yichang, Hubei, China.
3   China Three Gorges University, College of Basic Medical Sciences, The Institute of Infection and Inflammation, Yichang, China.
,
Binbin Liu 
2   China Three Gorges University, College of Basic Medical Sciences, Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, Yichang, Hubei, China.
3   China Three Gorges University, College of Basic Medical Sciences, The Institute of Infection and Inflammation, Yichang, China.
,
Lili Zou 
2   China Three Gorges University, College of Basic Medical Sciences, Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, Yichang, Hubei, China.
3   China Three Gorges University, College of Basic Medical Sciences, The Institute of Infection and Inflammation, Yichang, China.
› Author Affiliations Support The authors declare that the present study has received funding from the Hubei Office of Education Foundation (grant no. B2016022).
› Further Information
Also available at
   Permissions and Reprints

Abstract

Background In recent years, cyclooxygenase-2 (COX-2) has been identified as a cancer stem cell (CSC) marker in gliomas. Nevertheless, the clinical and prognostic significance of COX-2 in glioma patients remains controversial.

Objective To evaluate the correlation of COX-2 with the prognosis in glioma patients.

Methods Eligible studies on this subject were included, and pooled odd ratios (ORs) and hazard ratios (HRs) with 95% confidence intervals (95%CIs) were estimated. Publication bias was assessed through funnel plots, and heterogeneity and sensitivity were analyzed as well.

Results In the present study, 11 articles with a total of 641 patients were included. The high expression of COX-2 in glioma patients was negatively associated with overall survival (OS) (n = 11; HR = 2.26; 95%CI = 1.79–2.86), and the subgroup analysis showed no differences in OS between Asian (n = 5; HR = 2.16; 95%CI = 1.57–2.97) and non-Asian (n = 6; HR = 2.39; 95%CI = 1.69–3.38) glioma patients. The Begg funnel plots test indicated that there was no evident risk of publication bias in the meta-analysis.

Conclusion The present study suggests that COX-2 could be recommended as a useful pathological and prognostic biomarker in the clinical practice.

Resumo

Introdução Nos últimos anos, a ciclooxigenase-2 (COX-2) foi identificada como um marcador de células-tronco cancerígenas (CSC) em gliomas. No entanto, o significado clínico e prognóstico da COX-2 em pacientes com glioma permanece controverso.

Objetivo Avaliar a correlação da COX-2 com o prognóstico em pacientes com glioma.

Métodos Estudos elegíveis sobre este assunto foram incluídos e foram estimados odds ratios (ORs) e hazard ratios (HRs) com intervalos de confiança de 95% (IC 95%). O viés de publicação foi avaliado por meio de gráficos de funil, e a heterogeneidade e a sensibilidade também foram analisadas.

Resultados No presente estudo foram incluídos 11 artigos com um total de 641 pacientes. A alta expressão de COX-2 em pacientes com glioma foi negativamente associada à sobrevida global (OS) (n = 11; HR = 2,26; IC 95% = 1,79-2,86), e a análise de subgrupo não mostrou diferenças na OS entre asiáticos (n = 5; HR = 2,16; IC 95% = 1,57–2,97) e não asiáticos (n = 6; HR = 2,39; IC 95% = 1,69–3,38) pacientes com glioma. O teste de gráficos de funil de Begg indicou que não havia risco evidente de viés de publicação na metanálise.

Conclusão O presente estudo sugere que a COX-2 pode ser recomendada como um biomarcador patológico e prognóstico útil na prática clínica.

Keywords

Cyclooxygenase 2 - Glioma - Meta-Analysis - Survival

Palavras-chave

Ciclo-oxigenase 2 - Glioma - Metanálise - Sobrevida

Authors' Contributions

All authors have contributed to the intellectual content of the present paper and have made significant contributions to the conception and design, acquisition of data, or analysis and interpretation of data, have contributed to drafting or revising the article for intellectual content and approved the final version submitted for publication.




Publication History

Received: 20 October 2021

Accepted: 25 April 2022

Article published online:
29 December 2022

© 2022. Academia Brasileira de Neurologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil